iStent infinite shows long-term effectiveness in managing glaucoma

The iStent infinite effectively lowers intraocular pressure (IOP) and reduces the need for topical medications in patients with open-angle glaucoma, according to a poster presented at AGS 2025.

The multicenter, retrospective study included 64 eyes treated by 7 surgeons, with implantation performed either as a standalone procedure or alongside cataract surgery.

At 12-month follow-up, mean IOP had decreased from 18.1 mmHg to 13.8 mmHg, a 23% reduction (P = 0.001). The average number of IOP-lowering medications dropped by 51%, with 61% of eyes no longer requiring topical treatment compared to just 8% before implantation. Two-thirds of eyes achieved an IOP below 14 mmHg, and over a third reached levels below 12 mmHg.

The procedure was well tolerated, with no intraoperative complications. Reported adverse events were mild and resolved without lasting effects.

Reference
Trubnik V, et al. Third-Generation Trabecular Micro-bypass Stent Implantation With or Without Cataract Surgery: 12-Month Multicenter Outcomes in Eyes with Open-Angle Glaucoma. Poster presented at: American Glaucoma Society Annual Meeting; February 26–March 2, 2025; Washington, DC.